UB Professor, Researcher spearheads two bio-tech companies, hopes to put WNY on the map


AMHERST, N.Y. (WIVB) – The Buffalo-Niagara region is betting on bio-technology.  The state has spent millions on high-tech drug manufacturing facilities in the area. A UB Researcher is now spearheading two related start ups.

Jonathan Lovell is an Assistant Professor of Biomedical engineering at U.B. Now his research has led him to create two start up companies. Now he hopes to put Western New York on the map as a hub for bio technology.

One of his companies is called Abcombi Biosciences, which boosts access to vaccines and allows the vaccines to work more efficiently.

The second start-up is called  POP Biotechnologies. It uses nanomedicine to find a more reliable way to deliver anti-cancer drugs to tumors.says he has high hopes for the bio tech field here in Western New York.

Lovell said, “I think we’re going to start seeing some rewards soon. My goal is to try to create a medicine that can improve the health of people and reduce suffering in the world basically .”

Lovell’s work is an example of what this region is trying to achieve: As institutions like U.B. pump hundreds of millions of dollars into life sciences research.

Lovell said, “There is support from major players to try to do everything here. If we have everything we need to push things into the clinic here.”

Most of the people working in these start-ups are former students. But they come from all over the world. That includes Dyego Miranda.

He’s from Brazil, and the government is paying for him to study and do research in Buffalo. Miranda said, “I think the possibilities are endless, we have just scratched the surface because we have so much to learn and so much to discover.”

Lovel said, “There are several health biotech companies in the area and I think the state is putting a lot of support behind biotech in Buffalo.”

As the company grows, Lovell’s goal is to keep it here- so the area can benefit. His next step is to create a business plan to begin clinical trials at area hospitals. But to bring something like this to market could cost millions if not billions.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Now